Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Heat-and-Cold treatment offers hope for men with spreading prostate cancer

NCT ID NCT07237399

Disease control Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at using heat or cold to destroy small clusters of prostate cancer that have spread to other parts of the body. It is for men who cannot have standard radiation therapy. The goal is to control the cancer with a quick, low-risk procedure that allows a fast recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with oligometastatic prostate cancer, characterized by 1-5 metastases who are no longer eligible for or refuse SBRT

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * \> 18 years old * PCa, treated with curative intent (radical prostatectomy, primary radiotherapy, or a combination of both) and oligorecurrent/oligopersistent metastasis (1 - 5 lesions) on imaging (PSMA-PET, CT, MRI). * Recurrence or progression of metastases on imaging (PSMA-PET, CT, MRI) that cannot be treated with SBRT, either due to a history of previous high-dose radiotherapy with dose constraints, because SBRT is technically unfeasible or unsafe for the specific lesions, or because the patient refuses to undergo SBRT. * PSMA-positive lesion * Lesions up to 4 cm that are suitable and safe for TA with an anticipated high rate of technical success * 'Eastern Cooperative Oncology Group' (ECOG) performance status of 2 or less. * Patients can be androgen sensitive (mHSPC) or castration resistant (mCRPC). * All patients will be discussed at the Multidisciplinary Tumor Board. Exclusion criteria: * \<18y * Severe comorbidity which limits the further life expectancy of the patient to \< 2 years (opinion of the physician) and no malignancies \< 2 years ago except for non-melanoma skin cancer and non-muscle invasive bladder cancer. * No local radical treatment of the primary tumor was performed. * Lack of compliance * Absence of consent of the patient * Location: intracranial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ablation techniques are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ablation techniques Oligometastatic prostate cancer (OMPC) Prostate cancer (adenocarcinoma)

Contacts and locations

Locations

  • Ghent University Hospital

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.